Literature DB >> 17141202

Cholesterol reduction by methyl-beta-cyclodextrin attenuates the delta opioid receptor-mediated signaling in neuronal cells but enhances it in non-neuronal cells.

Peng Huang1, Wei Xu, Su-In Yoon, Chongguang Chen, Parkson Lee-Gau Chong, Lee-Yuan Liu-Chen.   

Abstract

Opioid receptors have been shown to be located in and regulated by lipid rafts/caveolae in caveolin-rich non-neuronal cells. Here, we found that caveolin-1 level was very low in rat brain and undetectable in NG108-15 cells, which endogenously express delta opioid receptors (DOR). Rat caudate putamen (CPu) membranes, NG108-15 cells and CHO cells stably transfected with FLAG-mouse-DOR (CHO-FLAG-mDOR) were homogenized, sonicated in a detergent-free 0.5M Na(2)CO(3) buffer and fractionated through discontinuous or continuous sucrose density gradients. About 70% of opioid receptors in CPu and DOR in both cell lines were present in low-density (5-20% sucrose) membrane domains enriched in cholesterol and ganglioside M1 (GM1), characteristics of lipid rafts in plasma membranes. In both cells, stimulation with permeable or non-permeable full agonists, but not with partial or inverse agonists, for 30min shifted approximately 25% of DORs out of rafts, by a naloxone-reversible and pertussis toxin-insensitive mechanism, which may undergo internalization. Methyl-beta-cyclodextrin (MCD) treatment greatly reduced cholesterol and shifted DOR to higher density fractions and decreased DPDPE affinities. MCD treatment attenuated DPDPE-induced [(35)S]GTPgammaS binding in CPu and NG108-15 cells, but enhanced it in CHO-FLAG-mDOR cells. In CHO-FLAG-mDOR cells, G(alphai) co-immunoprecipitated with caveolin-1, which was shown to inhibit G(alphai/o), and MCD treatment dramatically reduced the association leading to disinhibition. Thus, although localization in rafts and agonist-induced shift of DOR are independent of caveolin-1, lipid rafts sustain DOR-mediated signaling in caveolin-deficient neuronal cells, but appear to inhibit it in caveolin-enriched non-neuronal cells. Cholesterol-dependent association of caveolin-1 with and the resulting inhibition of G proteins may be a contributing factor.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17141202      PMCID: PMC2583444          DOI: 10.1016/j.bcp.2006.10.032

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  65 in total

1.  Opioid regulation of the mouse delta-opioid receptor expressed in human embryonic kidney 293 cells.

Authors:  G Bot; A D Blake; S Li; T Reisine
Journal:  Mol Pharmacol       Date:  1997-08       Impact factor: 4.436

2.  Transbilayer distribution of cholesterol is modified in brain synaptic plasma membranes of knockout mice deficient in the low-density lipoprotein receptor, apolipoprotein E, or both proteins.

Authors:  U Igbavboa; N A Avdulov; S V Chochina; W G Wood
Journal:  J Neurochem       Date:  1997-10       Impact factor: 5.372

3.  Identification of peptide and protein ligands for the caveolin-scaffolding domain. Implications for the interaction of caveolin with caveolae-associated proteins.

Authors:  J Couet; S Li; T Okamoto; T Ikezu; M P Lisanti
Journal:  J Biol Chem       Date:  1997-03-07       Impact factor: 5.157

4.  Identification of caveolin and caveolin-related proteins in the brain.

Authors:  P L Cameron; J W Ruffin; R Bollag; H Rasmussen; R S Cameron
Journal:  J Neurosci       Date:  1997-12-15       Impact factor: 6.167

5.  Delta and kappa opioid receptors are differentially regulated by dynamin-dependent endocytosis when activated by the same alkaloid agonist.

Authors:  P Chu; S Murray; D Lissin; M von Zastrow
Journal:  J Biol Chem       Date:  1997-10-24       Impact factor: 5.157

6.  Bradykinin sequesters B2 bradykinin receptors and the receptor-coupled Galpha subunits Galphaq and Galphai in caveolae in DDT1 MF-2 smooth muscle cells.

Authors:  W F de Weerd; L M Leeb-Lundberg
Journal:  J Biol Chem       Date:  1997-07-11       Impact factor: 5.157

7.  Rafts defined: a report on the Keystone Symposium on Lipid Rafts and Cell Function.

Authors:  Linda J Pike
Journal:  J Lipid Res       Date:  2006-04-27       Impact factor: 5.922

8.  Delta opioid modulation of the binding of guanosine-5'-O-(3-[35S]thio)triphosphate to NG108-15 cell membranes: characterization of agonist and inverse agonist effects.

Authors:  P G Szekeres; J R Traynor
Journal:  J Pharmacol Exp Ther       Date:  1997-12       Impact factor: 4.030

9.  Ischemic preconditioning and morphine-induced cardioprotection involve the delta (delta)-opioid receptor in the intact rat heart.

Authors:  J J Schultz; A K Hsu; G J Gross
Journal:  J Mol Cell Cardiol       Date:  1997-08       Impact factor: 5.000

10.  Activation of the cloned human kappa opioid receptor by agonists enhances [35S]GTPgammaS binding to membranes: determination of potencies and efficacies of ligands.

Authors:  J Zhu; L Y Luo; J G Li; C Chen; L Y Liu-Chen
Journal:  J Pharmacol Exp Ther       Date:  1997-08       Impact factor: 4.030

View more
  35 in total

1.  Cholesterol, mood, and vascular health: Untangling the relationship: Does low cholesterol predispose to depression and suicide, or vice versa?

Authors:  Jess G Fiedorowicz; William G Haynes
Journal:  Curr Psychiatr       Date:  2010-07

Review 2.  Membrane functional organisation and dynamic of mu-opioid receptors.

Authors:  André Lopez; Laurence Salomé
Journal:  Cell Mol Life Sci       Date:  2009-03-20       Impact factor: 9.261

3.  2-hydroxypropyl-beta-cyclodextrin raises hearing threshold in normal cats and in cats with Niemann-Pick type C disease.

Authors:  Sarah Ward; Patricia O'Donnell; Steven Fernandez; Charles H Vite
Journal:  Pediatr Res       Date:  2010-07       Impact factor: 3.756

4.  Sarcolemmal cholesterol and caveolin-3 dependence of cardiac function, ischemic tolerance, and opioidergic cardioprotection.

Authors:  Louise E See Hoe; Jan M Schilling; Emiri Tarbit; Can J Kiessling; Anna R Busija; Ingrid R Niesman; Eugene Du Toit; Kevin J Ashton; David M Roth; John P Headrick; Hemal H Patel; Jason N Peart
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-07-25       Impact factor: 4.733

5.  Agonist treatment did not affect association of mu opioid receptors with lipid rafts and cholesterol reduction had opposite effects on the receptor-mediated signaling in rat brain and CHO cells.

Authors:  Peng Huang; Wei Xu; Su-In Yoon; Chongguang Chen; Parkson Lee-Gau Chong; Ellen M Unterwald; Lee-Yuan Liu-Chen
Journal:  Brain Res       Date:  2007-10-12       Impact factor: 3.252

6.  Brain region-specific N-glycosylation and lipid rafts association of the rat mu opioid receptor.

Authors:  Peng Huang; Chongguang Chen; Wei Xu; Su-In Yoon; Ellen M Unterwald; John E Pintar; Yulin Wang; Parkson Lee-Gau Chong; Lee-Yuan Liu-Chen
Journal:  Biochem Biophys Res Commun       Date:  2007-10-31       Impact factor: 3.575

7.  Cholesterol and affective morbidity.

Authors:  Jess G Fiedorowicz; Narasimha M Palagummi; Ole Behrendtsen; William H Coryell
Journal:  Psychiatry Res       Date:  2009-12-06       Impact factor: 3.222

8.  Allosteric regulation of G protein-coupled receptor activity by phospholipids.

Authors:  Rosie Dawaliby; Cataldo Trubbia; Cédric Delporte; Matthieu Masureel; Pierre Van Antwerpen; Brian K Kobilka; Cédric Govaerts
Journal:  Nat Chem Biol       Date:  2015-11-16       Impact factor: 15.040

Review 9.  The function of G-protein coupled receptors and membrane cholesterol: specific or general interaction?

Authors:  Yamuna Devi Paila; Amitabha Chattopadhyay
Journal:  Glycoconj J       Date:  2008-12-04       Impact factor: 2.916

Review 10.  Contributions of quantitative proteomics to understanding membrane microdomains.

Authors:  Yu Zi Zheng; Leonard J Foster
Journal:  J Lipid Res       Date:  2009-07-03       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.